Overview
Vitrotest Europe is a high-technology manufacturer and supplier of enzyme immunoassay kits and raw materials for immunoassays, specializing in ELISA tests for diagnosing infectious diseases, allergies, and cancer. The company develops and manufactures native and recombinant antigens, monoclonal antibodies, and synthetic controls for laboratory tests. They also provide high-quality antibodies and are involved in creating innovative products for biotechnological production.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
Vitrotest Group to participate in MEDICA 2026!
From November 16 to 19, 2026, the world-renowned MEDICA exhibition will take place in Düsseldorf, Germany, traditionally bringing together leading medical industry professionals from more than 70 countries worldwide. During the exhibition, we will showcase a wide range of high-quality in vitro diagnostic products, including ELISA test kits and components for their production -
Recombinant Human Tissue Transglutaminase Successfully Developed for ELISA Applications
We are delighted to introduce our recombinant RP-50 human tissue transglutaminase (tTG), produced in the Escherichia coli expression system. The recombinant antigen demonstrated outstanding performance in the detection of anti-tTG IgA and anti-tTG IgG antibodies. In addition, it showed high stability and excellent reproducibility of assay results, making it a reliable antigen for immunodiagnostic
Vitrotest Group to participate in MEDICA 2025!
From November 17 to 20, 2025, the world-renowned MEDICA exhibition will take place in Düsseldorf, Germany, traditionally bringing together leading medical industry professionals from more than 70 countries worldwide. During the exhibition, we will showcase a wide range of high-quality in vitro diagnostic products, including ELISA test kits and components for their production -
New Matched Monoclonal Antibodies for Mycoplasma hominis Detection in Urogenital Samples
Our team is pleased to introduce matched pairs of monoclonal antibodies specifically targeting surface lipoproteins of Mycoplasma hominis. Designed for high-affinity binding, these antibodies enable sensitive and specific detection in urogenital clinical samples. They are ideally suited for developers of diagnostic tests and research-use-only (RUO) tools focused on reproductive tract infections.
New Matched Monoclonal Antibodies for Giardia lamblia Cyst Antigen Detection
Vitrotest has developed new matched pairs of monoclonal antibodies specific to Giardia lamblia cyst antigens. These antibodies are ideal for use in sandwich immunoassays such as ELISA and rapid tests. They are optimized for use in diagnostic and research assays, and will be of particular interest to manufacturers of in vitro diagnostic kits.
Protein G
Vitrotest is pleased to announce the expansion of its product portfolio with the introduction of recombinant Protein G. This streptococcal surface protein from Group G is widely used in immunological applications. It serves as an effective tool for the development of affinity purification carriers for antibodies, as well as for conjugation and other
Industry
Bank accounts
Registered as a VAT taxpayer on 2020-07-14. Active
09 1020 5226 0000 6802 0718 6739- 14 1020 5226 0000 6602 0718 6747
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Mar 9, 2020 | Aid for SME access to finance — aid for start-ups | $205.1K$205,139 | Dyrektor Narodowego Centrum Badań i Rozwoju |
Tenders
No recorded participation in tenders.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
In the case of a one-person management board, the member of the management board is authorized to represent the company independently. If the management board is multi-member, each member of the management board is authorized to represent the company and act on its behalf independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Ihor Nikolaienko (55) | 500 | $6,753.11 | 50% |
Galyna Rayevska (51) | 500 | $6,753.11 | 50% |
Beneficial owners
| Person | Rights | |
|---|---|---|
Ihor Nikolaienko (55)  | Shareholder of a limited liability company, 25000.0 PLN | |
Galyna Rayevska (51)  | Shareholder of a limited liability company, 25000.0 PLN |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| BioceltixS.A. | $616,315.97 | bioceltix.com | ||
| CTI Clinical Trial And Consulting Services Polandsp. z o.o. | $527,145.56 | ctifacts.com | ||
| VET Cell Techsp. z o.o. | $483,439.81 | vetcelltech.com | ||
| Medicofarma BiotechS.A. | $314,882.33 | medicofarmabiotech.pl | ||
| TCIsp. z o.o. | $218,471.87 | tci.pl | ||
| Nexbiosp. z o.o. | $186,582.40 | nexbio.pl | ||
| Chemlabsp. z o.o. | $144,354.49 | chemlab.com.pl | ||
| Relvosp. z o.o. | $120,693.26 | relvo.pl | ||
| AM Lab Solutionssp. z o.o. | $100,896.70 | amsolutions.pl | ||
| Sentisasp. z o.o. | $98,401.32 | sentisa.com |
Change history
| Date | Event | |
|---|---|---|
| 2023-08-09 | Share capital change (5,000.00 PLN → 50,000.00 PLN) | |
| 2020-07-06 | Address change (Ul. Wałbrzyska 17/2, 52-314, Wrocław → Ul. Krakowska 139-155, 50-428, Wrocław) | |
| 2020-06-19 | Entered in the register |
FAQ
Last updated: 2026-07-05